{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:29:02Z","timestamp":1769228942599,"version":"3.49.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00115-024-01640-6","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T18:01:47Z","timestamp":1710784907000},"page":"316-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myasthenia gravis\u00a0\u2013 Genderaspekte und Familienplanung","Myasthenia gravis\u2014Gender aspects and family planning"],"prefix":"10.1007","volume":"95","author":[{"given":"Sarah","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Verlohren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meret","family":"Herdick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"1640_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob\u00a0D, Brunner\u00a0N, Namba\u00a0T, Pagala\u00a0M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37:141\u2013149","journal-title":"Muscle Nerve"},{"key":"1640_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki\u00a0A 3rd, Barohn\u00a0RJ, Ernstoff\u00a0RM et\u00a0al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16\u201323","journal-title":"Neurology"},{"key":"1640_CR3","doi-asserted-by":"crossref","unstructured":"Wartmann H, Hoffmann S, Ruck T, Nelke C, Deiters B, Volmer T (2023) Incidence, prevalence, hospitalization rates and treatment patterns in myasthenia gravis: A\u00a010-year real-world data analysis of German claims data. Neuroepidemiology","DOI":"10.1159\/000529583"},{"key":"1640_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr\u00a0AS, Cardwell\u00a0CR, McCarron\u00a0PO, McConville\u00a0J (2010) A\u00a0systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10:46","journal-title":"BMC Neurol"},{"key":"1640_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/00207454.2018.1529669","volume":"129","author":"A Asmail","year":"2019","unstructured":"Asmail\u00a0A, Kesler\u00a0A, Kolb\u00a0H, Drory\u00a0VE, Karni\u00a0A (2019) A\u00a0tri-modal distribution of age-of-onset in female patients with myasthenia gravis is associated with the gender-related clinical differences. Int J Neurosci 129:313\u2013319","journal-title":"Int J Neurosci"},{"key":"1640_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3988\/jcn.2012.8.3.161","volume":"8","author":"ZF Mao","year":"2012","unstructured":"Mao\u00a0ZF, Mo\u00a0XA, Qin\u00a0C, Lai\u00a0YR, Hackett\u00a0ML (2012) Incidence of thymoma in myasthenia gravis: a\u00a0systematic review. J\u00a0Clin Neurol 8:161\u2013169","journal-title":"J Clin Neurol"},{"key":"1640_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1046\/j.1365-2249.1997.d01-881.x","volume":"107","author":"A Hoedemaekers","year":"1997","unstructured":"Hoedemaekers\u00a0A, Graus\u00a0Y, van Breda Vriesman\u00a0P, de Baets\u00a0M (1997) Age- and sex-related resistance to chronic experimental autoimmune myasthenia gravis (EAMG) in Brown Norway rats. Clin Exp Immunol 107:189\u2013197","journal-title":"Clin Exp Immunol"},{"key":"1640_CR8","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1172\/JCI81894","volume":"126","author":"N Dragin","year":"2016","unstructured":"Dragin\u00a0N, Bismuth\u00a0J, Cizeron-Clairac\u00a0G et\u00a0al (2016) Estrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases. J\u00a0Clin Investig 126:1525\u20131537","journal-title":"J Clin Investig"},{"key":"1640_CR9","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1210\/en.2004-1003","volume":"146","author":"P Nancy","year":"2005","unstructured":"Nancy\u00a0P, Berrih-Aknin\u00a0S (2005) Differential estrogen receptor expression in autoimmune myasthenia gravis. Endocrinology 146:2345\u20132353","journal-title":"Endocrinology"},{"key":"1640_CR10","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer\u00a0S, Jacobi\u00a0J, Schilling\u00a0R et\u00a0al (2022) Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J\u00a0Neurol 269:3050\u20133063","journal-title":"J Neurol"},{"key":"1640_CR11","doi-asserted-by":"crossref","unstructured":"Lee I, Kaminski HJ, Xin H, Cutter G (2018) Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry. Muscle Nerve","DOI":"10.1007\/978-3-319-73585-6_11"},{"key":"1640_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000512077","volume":"84","author":"AR Abuzinadah","year":"2021","unstructured":"Abuzinadah\u00a0AR, Alanazy\u00a0MH, Butt\u00a0NS, Barohn\u00a0RJ, Dimachkie\u00a0MM (2021) Exacerbation rate in generalized Myasthenia Gravis and its predictors. Eur Neurol 84:43\u201348","journal-title":"Eur Neurol"},{"key":"1640_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12955-020-01549-z","volume":"18","author":"D Dong","year":"2020","unstructured":"Dong\u00a0D, Chong\u00a0MK, Wu\u00a0Y et\u00a0al (2020) Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual Life Outcomes 18:296","journal-title":"Health Qual Life Outcomes"},{"key":"1640_CR14","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","volume":"94","author":"B Neumann","year":"2020","unstructured":"Neumann\u00a0B, Angstwurm\u00a0K, Mergenthaler\u00a0P et\u00a0al (2020) Myasthenic crisis demanding mechanical ventilation: a\u00a0multicenter analysis of 250 cases. Neurology 94:e299\u2013e313","journal-title":"Neurology"},{"key":"1640_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke\u00a0C, Stascheit\u00a0F, Eckert\u00a0C et\u00a0al (2022) Independent risk factors for myasthenic crisis and disease exacerbation in a\u00a0retrospective cohort of myasthenia gravis patients. J\u00a0Neuroinflammation 19:89","journal-title":"J Neuroinflammation"},{"key":"1640_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/WNO.0000000000000276","volume":"36","author":"JH Peragallo","year":"2016","unstructured":"Peragallo\u00a0JH, Bitrian\u00a0E, Kupersmith\u00a0MJ et\u00a0al (2016) Relationship between age, gender, and race in patients presenting with myasthenia gravis with only ocular manifestations. J\u00a0Neuro Ophthalmology 36:29\u201332","journal-title":"J Neuro Ophthalmology"},{"key":"1640_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ensci.2016.04.005","volume":"4","author":"A Karni","year":"2016","unstructured":"Karni\u00a0A, Asmail\u00a0A, Drory\u00a0VE, Kolb\u00a0H, Kesler\u00a0A (2016) Characterization of patients with ocular myasthenia gravis\u2014a case series. eNeurologicalSci 4:30\u201333","journal-title":"eNeurologicalSci"},{"key":"1640_CR18","doi-asserted-by":"publisher","first-page":"632","DOI":"10.5694\/j.1326-5377.1986.tb112345.x","volume":"144","author":"GA Nicholson","year":"1986","unstructured":"Nicholson\u00a0GA, Wilby\u00a0J, Tennant\u00a0C (1986) Myasthenia-gravis\u2014the problem of a\u00a0psychiatric misdiagnosis. Med J Aust 144:632","journal-title":"Med J Aust"},{"key":"1640_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","volume":"21","author":"AR Punga","year":"2022","unstructured":"Punga\u00a0AR, Maddison\u00a0P, Heckmann\u00a0JM, Guptill\u00a0JT, Evoli\u00a0A (2022) Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol 21:176\u2013188","journal-title":"Lancet Neurol"},{"key":"1640_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","volume":"21","author":"MG Huijbers","year":"2022","unstructured":"Huijbers\u00a0MG, Marx\u00a0A, Plomp\u00a0JJ, Le Panse\u00a0R, Phillips\u00a0WD (2022) Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol 21:163\u2013175","journal-title":"Lancet Neurol"},{"key":"1640_CR21","doi-asserted-by":"crossref","unstructured":"Citirak G, Cejvanovic S, Andersen H, Vissing J (2016) Effect of gender, disease duration and treatment on muscle strength in Myasthenia Gravis. PLoS ONE 11:","DOI":"10.1371\/journal.pone.0164092"},{"key":"1640_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/mus.25539","volume":"56","author":"A Abraham","year":"2017","unstructured":"Abraham\u00a0A, Breiner\u00a0A, Barnett\u00a0C et\u00a0al (2017) Electrophysiological testing is correlated with myasthenia gravis severity. Muscle Nerve 56:445\u2013448","journal-title":"Muscle Nerve"},{"key":"1640_CR23","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1038\/s41598-023-30154-5","volume":"13","author":"M Tomschik","year":"2023","unstructured":"Tomschik\u00a0M, Renaud\u00a0E, Jager\u00a0F et\u00a0al (2023) The diagnostic and prognostic utility of repetitive nerve stimulation in patients with myasthenia gravis. Sci Rep 13:2985","journal-title":"Sci Rep"},{"key":"1640_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ana.410120406","volume":"12","author":"SJ Oh","year":"1982","unstructured":"Oh\u00a0SJ, Eslami\u00a0N, Nishihira\u00a0T et\u00a0al (1982) Electrophysiological and clinical correlation in myasthenia gravis. Ann Neurol 12:348\u2013354","journal-title":"Ann Neurol"},{"key":"1640_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1196\/annals.1254.054","volume":"998","author":"R Mantegazza","year":"2003","unstructured":"Mantegazza\u00a0R, Baggi\u00a0F, Antozzi\u00a0C et\u00a0al (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 998:413\u2013423","journal-title":"Ann N Y Acad Sci"},{"key":"1640_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/mus.27331","volume":"64","author":"JLS Thomsen","year":"2021","unstructured":"Thomsen\u00a0JLS, Vinge\u00a0L, Harbo\u00a0T, Andersen\u00a0H (2021) Gender differences in clinical outcomes in myasthenia gravis: a\u00a0prospective cohort study. Muscle Nerve 64:538\u2013544","journal-title":"Muscle Nerve"},{"key":"1640_CR27","first-page":"255","volume":"86","author":"J Suh","year":"2013","unstructured":"Suh\u00a0J, Goldstein\u00a0JM, Nowak\u00a0RJ (2013) Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med 86:255\u2013260","journal-title":"Yale J Biol Med"},{"key":"1640_CR28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr.","year":"2017","unstructured":"Howard\u00a0JF Jr., Utsugisawa\u00a0K, Benatar\u00a0M et\u00a0al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a\u00a0phase\u00a03, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986","journal-title":"Lancet Neurol"},{"key":"1640_CR29","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1212\/NXI.0000000000000507","volume":"5","author":"I Lee","year":"2018","unstructured":"Lee\u00a0I, Kaminski\u00a0HJ, McPherson\u00a0T, Feese\u00a0M, Cutter\u00a0G (2018) Gender differences in prednisone adverse effects: survey result from the MG registry. Neurol Neuroimmunol Neuroinflamm 5:e507","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1640_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","volume":"48","author":"OP Soldin","year":"2009","unstructured":"Soldin\u00a0OP, Mattison\u00a0DR (2009) Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 48:143\u2013157","journal-title":"Clin Pharmacokinet"},{"key":"1640_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.gaceta.2018.04.003","volume":"33","author":"S Heidari","year":"2019","unstructured":"Heidari\u00a0S, Babor\u00a0TF, De Castro\u00a0P, Tort\u00a0S, Curno\u00a0M (2019) Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Gac Sanit 33:203\u2013210","journal-title":"Gac Sanit"},{"key":"1640_CR32","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr.","year":"2021","unstructured":"Howard\u00a0JF Jr., Bril\u00a0V, Vu\u00a0T et\u00a0al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a\u00a0multicentre, randomised, placebo-controlled, phase\u00a03\u00a0trial. Lancet Neurol 20:526\u2013536","journal-title":"Lancet Neurol"},{"key":"1640_CR33","first-page":"S2","volume":"65","author":"T Vu","year":"2022","unstructured":"Vu\u00a0T, Meisel\u00a0A, Mantegazza\u00a0R et\u00a0al (2022) Long-term efficacy and safety of ravulizumab, a\u00a0long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized Myasthenia Gravis: results from the phase\u00a03 champion mg open-label extension. Muscle Nerve 65:S2\u2013S3","journal-title":"Muscle Nerve"},{"key":"1640_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr.","year":"2023","unstructured":"Howard\u00a0JF Jr., Bresch\u00a0S, Genge\u00a0A et\u00a0al (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a\u00a0randomised, double-blind, placebo-controlled, phase\u00a03\u00a0study. Lancet Neurol 22:395\u2013406","journal-title":"Lancet Neurol"},{"key":"1640_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril\u00a0V, Druzdz\u00a0A, Grosskreutz\u00a0J et\u00a0al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a\u00a0randomised, double-blind, placebo-controlled, adaptive phase\u00a03\u00a0study. Lancet Neurol 22:383\u2013394","journal-title":"Lancet Neurol"},{"key":"1640_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/mus.24556","volume":"52","author":"S Ohlraun","year":"2015","unstructured":"Ohlraun\u00a0S, Hoffmann\u00a0S, Klehmet\u00a0J et\u00a0al (2015) Impact of myasthenia gravis on family planning: how do women with myasthenia gravis decide and why? Muscle Nerve 52:371\u2013379","journal-title":"Muscle Nerve"},{"key":"1640_CR37","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s00115-010-2995-7","volume":"81","author":"J Klehmet","year":"2010","unstructured":"Klehmet\u00a0J, Dudenhausen\u00a0J, Meisel\u00a0A (2010) Course and treatment of myasthenia gravis during pregnancy. Nervenarzt 81:956\u2013962","journal-title":"Nervenarzt"},{"key":"1640_CR38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders\u00a0DB, Wolfe\u00a0GI, Benatar\u00a0M et\u00a0al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419\u2013425","journal-title":"Neurology"},{"key":"1640_CR39","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe\u00a0GI, Kaminski\u00a0HJ, Cutter\u00a0GR (2016) Randomized trial of thymectomy in Myasthenia Gravis. N\u00a0Engl J Med 375:2006\u20132007","journal-title":"N Engl J Med"},{"key":"1640_CR40","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3389\/fneur.2020.00554","volume":"11","author":"NE Gilhus","year":"2020","unstructured":"Gilhus\u00a0NE (2020) Myasthenia gravis can have consequences for pregnancy and the developing child. Front Neurol 11:554","journal-title":"Front Neurol"},{"key":"1640_CR41","doi-asserted-by":"crossref","unstructured":"Cimpoca-Raptis BA, Ciobanu AM, Gica N, Peltecu G, Mitrea D, Panaitescu AM (2021) Fetal surveillance in pregnancies with myasthenia Gravis. Medicina 57:","DOI":"10.3390\/medicina57111277"},{"key":"1640_CR42","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1212\/01.WNL.0000082725.21444.EC","volume":"61","author":"JM Hoff","year":"2003","unstructured":"Hoff\u00a0JM, Daltveit\u00a0AK, Gilhus\u00a0NE (2003) Myasthenia gravis: consequences for pregnancy, delivery, and the newborn. Neurology 61:1362\u20131366","journal-title":"Neurology"},{"key":"1640_CR43","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nmd.2017.01.021","volume":"27","author":"RD Ducci","year":"2017","unstructured":"Ducci\u00a0RD, Lorenzoni\u00a0PJ, Kay\u00a0CS, Werneck\u00a0LC, Scola\u00a0RH (2017) Clinical follow-up of pregnancy in myasthenia gravis patients. Neuromuscul Disord 27:352\u2013357","journal-title":"Neuromuscul Disord"},{"key":"1640_CR44","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1515\/jpm-2020-0163","volume":"48","author":"L Nicholls-Dempsey","year":"2020","unstructured":"Nicholls-Dempsey\u00a0L, Czuzoj-Shulman\u00a0N, Abenhaim\u00a0HA (2020) Maternal and neonatal outcomes among pregnant women with myasthenia gravis. J\u00a0Perinat Med 48:793\u2013798","journal-title":"J Perinat Med"},{"key":"1640_CR45","doi-asserted-by":"publisher","first-page":"e16100","DOI":"10.1111\/ene.16100","volume":"31","author":"L O\u2019Connor","year":"2024","unstructured":"O\u2019Connor\u00a0L, Malmestrom\u00a0C, Da Silva Rodrigues\u00a0R, Brauner\u00a0S, Wikstrom\u00a0AK, Punga\u00a0AR (2024) Pregnancy outcomes for women with myasthenia gravis and their newborns: a\u00a0nationwide register-based cohort study. Eur J Neurol 31:e16100","journal-title":"Eur J Neurol"},{"key":"1640_CR46","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/mus.880130808","volume":"13","author":"RG Bashuk","year":"1990","unstructured":"Bashuk\u00a0RG, Krendel\u00a0DA (1990) Myasthenia gravis presenting as weakness after magnesium administration. Muscle Nerve 13:708\u2013712","journal-title":"Muscle Nerve"},{"key":"1640_CR47","first-page":"35S","volume":"48","author":"BA Cohen","year":"1976","unstructured":"Cohen\u00a0BA, London\u00a0RS, Goldstein\u00a0PJ (1976) Myasthenia gravis and preeclampsia. Obstet Gynecol 48:35S\u201337S","journal-title":"Obstet Gynecol"},{"key":"1640_CR48","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/ene.13788","volume":"25","author":"NE Gilhus","year":"2018","unstructured":"Gilhus\u00a0NE, Hong\u00a0Y (2018) Maternal myasthenia gravis represents a\u00a0risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. Eur J Neurol 25:1402\u20131409","journal-title":"Eur J Neurol"},{"key":"1640_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0301-2115(02)00051-9","volume":"104","author":"J Djelmis","year":"2002","unstructured":"Djelmis\u00a0J, Sostarko\u00a0M, Mayer\u00a0D, Ivanisevic\u00a0M (2002) Myasthenia gravis in pregnancy: report on 69\u00a0cases. Eur J Obstet Gynecol Reprod Biol 104:21\u201325","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1640_CR50","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/1753495X211041899","volume":"15","author":"H Banner","year":"2022","unstructured":"Banner\u00a0H, Niles\u00a0KM, Ryu\u00a0M, Sermer\u00a0M, Bril\u00a0V, Murphy\u00a0KE (2022) Myasthenia gravis in pregnancy: systematic review and case series. Obstet Med 15:108\u2013117","journal-title":"Obstet Med"},{"key":"1640_CR51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-0043-118475","volume":"45","author":"M Schroeter","year":"2018","unstructured":"Schroeter\u00a0M, Thayssen\u00a0G, Kaiser\u00a0J (2018) Myasthenia gravis\u2014exacerbation and crisis. Aktuel Neurol 45:271\u2013277","journal-title":"Aktuel Neurol"},{"key":"1640_CR52","unstructured":"Wiendl H, Andreas M Diagnostik und Therapie myasthener Syndrome, S2k-Leitlinie, 2022, DGN. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie"},{"key":"1640_CR53","doi-asserted-by":"crossref","unstructured":"Draxler J, Verlohren S, Hoffmann S et al (2024) Pregnancy in myasthenia gravis: a retrospective analysis of maternal and neonatal outcome from a large tertiary care center in Germany. Accepted in Arch Gynecol Obstet","DOI":"10.1007\/s00404-024-07436-y"},{"key":"1640_CR54","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.1468-1331.2009.02689.x","volume":"16","author":"JC Wen","year":"2009","unstructured":"Wen\u00a0JC, Liu\u00a0TC, Chen\u00a0YH, Chen\u00a0SF, Lin\u00a0HC, Tsai\u00a0WC (2009) No increased risk of adverse pregnancy outcomes for women with myasthenia gravis: a\u00a0nationwide population-based study. Eur J Neurol 16:889\u2013894","journal-title":"Eur J Neurol"},{"key":"1640_CR55","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1086\/506257","volume":"79","author":"K Hoffmann","year":"2006","unstructured":"Hoffmann\u00a0K, Muller\u00a0JS, Stricker\u00a0S et\u00a0al (2006) Escobar syndrome is a\u00a0prenatal myasthenia caused by disruption of the acetylcholine receptor fetal gamma subunit. Am J Hum Genet 79:303\u2013312","journal-title":"Am J Hum Genet"},{"key":"1640_CR56","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.c.31723","volume":"181","author":"I Filges","year":"2019","unstructured":"Filges\u00a0I, Tercanli\u00a0S, Hall\u00a0JG (2019) Fetal arthrogryposis: challenges and perspectives for prenatal detection and management. Am J Med Genet C Semin Med Genet 181:327\u2013336","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"1640_CR57","doi-asserted-by":"crossref","unstructured":"Allen NM, O\u2019Rahelly M, Eymard B et\u00a0al (2023) The emerging spectrum of foetal acetylcholine receptor antibody-associated disorders (FARAD). Brain","DOI":"10.1016\/j.nmd.2023.07.445"},{"key":"1640_CR58","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1212\/WNL.0b013e3181c34a65","volume":"73","author":"J Reimann","year":"2009","unstructured":"Reimann\u00a0J, Jacobson\u00a0L, Vincent\u00a0A, Kornblum\u00a0C (2009) Endplate destruction due to maternal antibodies in arthrogryposis multiplex congenita. Neurology 73:1806\u20131808","journal-title":"Neurology"},{"key":"1640_CR59","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1172\/JCI119048","volume":"98","author":"S Riemersma","year":"1996","unstructured":"Riemersma\u00a0S, Vincent\u00a0A, Beeson\u00a0D et\u00a0al (1996) Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J\u00a0Clin Invest 98:2358\u20132363","journal-title":"J Clin Invest"},{"key":"1640_CR60","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s42466-023-00280-6","volume":"5","author":"M Wassenberg","year":"2023","unstructured":"Wassenberg\u00a0M, Hahn\u00a0A, Muck\u00a0A, Kramer\u00a0HH (2023) Maternal immunoglobulin treatment can reduce severity of fetal acetylcholine receptor antibody-associated disorders (FARAD). Neurol Res Pract 5:58","journal-title":"Neurol Res Pract"},{"key":"1640_CR61","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite\u00a0MI, Jacob\u00a0S, Viegas\u00a0S et\u00a0al (2008) IgG\u00a01 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis. Brain 131:1940\u20131952","journal-title":"Brain"},{"key":"1640_CR62","doi-asserted-by":"crossref","unstructured":"Koneczny I, Myasthenia Gravis HR (2019) Pathogenic effects of autoantibodies on neuromuscular architecture. Cells 8:","DOI":"10.3390\/cells8070671"},{"key":"1640_CR63","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejogrb.2011.09.027","volume":"159","author":"JM Hoff","year":"2011","unstructured":"Hoff\u00a0JM, Loane\u00a0M, Gilhus\u00a0NE, Rasmussen\u00a0S, Daltveit\u00a0AK (2011) Arthrogryposis multiplexa congenita: an epidemiologic study of nearly 9\u00a0million births in 24 EUROCAT registers. Eur J Obstet Gynecol Reprod Biol 159:347\u2013350","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1640_CR64","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1468-1331.2006.01538.x","volume":"14","author":"JM Hoff","year":"2007","unstructured":"Hoff\u00a0JM, Daltveit\u00a0AK, Gilhus\u00a0NE (2007) Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 14:38\u201343","journal-title":"Eur J Neurol"},{"key":"1640_CR65","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1212\/WNL.0000000000003339","volume":"87","author":"MI Boldingh","year":"2016","unstructured":"Boldingh\u00a0MI, Maniaol\u00a0AH, Brunborg\u00a0C, Weedon-Fekjaer\u00a0H, Verschuuren\u00a0JJ, Tallaksen\u00a0CM (2016) Increased risk for clinical onset of myasthenia gravis during the postpartum period. Neurology 87:2139\u20132145","journal-title":"Neurology"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01640-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-024-01640-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01640-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T12:02:20Z","timestamp":1712923340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-024-01640-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1640"],"URL":"https:\/\/doi.org\/10.1007\/s00115-024-01640-6","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"23 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Hoffmann erhielt Honorare von Alexion, argenx, Roche und UCB f\u00fcr Vortr\u00e4ge und Teilnahme an wissenschaftlichen Beir\u00e4ten und ist Mitglied des \u00e4rztlichen Beirats der Deutschen Myasthenie Gesellschaft (DMG). S.\u00a0Verlohren erhielt Honorare von Alexion f\u00fcr Vortr\u00e4ge und Teilnahme an wissenschaftlichen Beir\u00e4ten. M.\u00a0Herdick erhielt Honorar von argenx f\u00fcr einen Vortrag.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}